[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pain-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pain-management":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,177,0,25,[9,49,78,103,130,160,182,208,232,254,287,309,335,368,396,427,451,474,500,524,544,563,587,621,647],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652113","qlesp-block-versus-penglfcn-block-for-total-hip-arthroplasty-100652113",false,"NCT07771829","QLESP Block Versus PENG+LFCN Block for Total Hip Arthroplasty","Comparison of Ultrasound-Guided QLESP Block Versus Pericapsular Nerve Group Block Combined With Lateral Femoral Cutaneous Nerve Block on Postoperative Analgesia and Functional Recovery in Total Hip Arthroplasty: A Randomized Controlled Trial","QLESP","Inclusion Criteria:\n\n* Age 18 to 70 years\n* Scheduled for elective unilateral total hip arthroplasty via posterolateral approach\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body mass index (BMI) \\\u003C 35 kg\u002Fm²\n* Ability to understand pain scoring and patient-controlled analgesia (PCA) use\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to local anesthetics (ropivacaine)\n* Long-term opioid use or chronic pain history requiring regular analgesic use\n* Active malignancy or infection at the puncture site\n* Severe psychiatric disorders or communication barriers\n* Severe cardiopulmonary disease\n* History of opioid abuse or substance dependence\n* Participation in another interventional clinical trial within 3 months prior to enrollment\n* Coagulation abnormalities\n* Pregnancy or breastfeeding\n* Any condition that, in the investigator's opinion, would compromise patient safety or data integrity","ALL","18 Years","70 Years",{"count":22,"type":23},136,"ESTIMATED","INTERVENTIONAL",[26],"NA","Total hip arthroplasty (THA) is a common surgery to replace damaged hip joints, but many patients experience significant pain after surgery, which can delay recovery and increase the need for strong pain medications (opioids). Nerve blocks are a technique where anesthetic medication is injected near specific nerves to reduce pain. This study compares two different ultrasound-guided nerve block techniques for pain control after THA: the QLESP block (a newer technique that targets two areas with a single injection) and the PENG block combined with the LFCN block (a currently used technique that targets nerves around the hip joint and the outer thigh). Participants in this study will be randomly assigned (like a coin flip) to receive either the QLESP block or the PENG+LFCN block after surgery. The study aims to determine which nerve block provides better pain relief and reduces the need for opioid pain medications in the first 24 hours after surgery. Pain scores, recovery of leg movement, time to first walk, length of hospital stay, and any side effects will also be compared between the two groups.",[29,30],"Pain Management","Arthroplasty Total Hip Replacement",[32,33,34,35,36],"Total Hip Arthroplasty","Nerve Block","Postoperative Analgesia","QLESP Block","PENG Block","RECRUITING","2026-08-19",{"date":40,"type":41},"2026-08-20","ACTUAL",{"date":38,"type":41},{"date":44,"type":23},"2027-02-28",{"name":46,"class":47},"Huazhong University of Science and Technology","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100649992","feasibility-and-acceptability-of-empowered-relief-for-american-indians-with-pain-during-and-after-cancer-treatment-100649992","NCT07742449","Feasibility and Acceptability of Empowered Relief for American Indians With Pain During and After Cancer Treatment","ejames3","Inclusion Criteria:\n\n* Identifies as American Indian\n* Has history of a cancer diagnosis\n* Is currently undergoing or has completed active cancer treatment\n* Experiences body pain most or every day\n* Pain duration at least 3 months\n* English fluency\n\nExclusion Criteria:\n\n* Significant psychological and cognitive impairment that limits one's ability to complete study tasks (completion of online survey, attending the Zoom-based ER class)\n* Life-threatening acute illness (e.g., infection, heart attack, injury)\n* No access to a computer, a smartphone, or a tablet",{"count":57,"type":23},70,[26],"This project will evaluate the feasibility and acceptability of Empowered Relief (ER) among American Indian adults who are currently receiving or have completed active cancer treatments at Stephenson Cancer Center (SCC). ER is a single-session, Zoom-based, 2-hour, skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily practice. ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety at 3 and 6 months post-treatment. Because of its brief, didactic nature and Zoom delivery, ER can accommodate large class sizes and may address accessibility disparities among underserved cancer populations. While ER is being studied across various non-cancer populations and has been adopted as standard of care in leading healthcare institutions in the U.S. and abroad, it has not been tested in American Indians with cancer.",[61,62,29,63,64],"Cancer","Pain","Chronic Pain","American Indian or Alaska Native",[61,66,62,63,67,68],"Cancer Survivor","Native American","American Indian","NOT_YET_RECRUITING","2026-08-18",{"date":40,"type":41},{"date":73,"type":23},"2026-08-01",{"date":75,"type":23},"2027-12",{"name":77,"class":47},"University of Oklahoma",{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100615930","evaluation-of-paro-a-therapeutic-assistance-robot-in-analgesic-management-during-the-placement-of-a-peripheral-intravenous-line-in-infants-and-children-100615930","NCT07299006","Evaluation of Paro, a Therapeutic Assistance Robot in Analgesic Management During the Placement of a Peripheral Intravenous Line in Infants and Children.","Evaluation of Paro, a Therapeutic Assistance Robot in Analgesic Management During the Placement of a Peripheral Intravenous Line in Infants and Children, a Multicenter Randomized Prospective Study.","PARO","Inclusion Criteria:\n\n1. Age between 12 months and 7 years.\n2. Requirement for peripheral intravenous catheterization (PIC).\n3. Written informed consent obtained from at least one parent or legal guardian.\n4. Affiliation with the national health insurance system (social security).\n\nExclusion Criteria:\n\n1. Requirement for contact isolation, including colonization or infection with multidrug-resistant organisms (MDROs).\n2. Visual or hearing impairment.\n3. Known psychiatric disorder.\n4. Inability to understand French.\n5. Life-threatening emergency requiring immediate intervention.\n6. Need for strong analgesic medication (e.g., morphine, ketamine, or intranasal analgesics).","1 Year","7 Years",{"count":89,"type":23},120,[26],"Peripheral intravenous catheterization is one of the most frequently performed procedures in pediatric emergency departments and hospital units. It is often associated with significant anxiety in both children and their parents, which may exacerbate the pain experienced during the procedure, as fear and pain are closely interrelated. Effective management of pain and anxiety is therefore essential to optimize the child's well-being in the short, medium, and long term.\n\nThe quality of pediatric analgesia relies on a multimodal approach combining pharmacological and non-pharmacological interventions. In recent years, several non-pharmacological strategies have been developed to reduce pain and anxiety. Among these, innovative technologies such as therapeutic assistance robots incorporating artificial intelligence have emerged; however, their clinical benefits remain to be established.\n\nThe present study aims to evaluate the effectiveness of PARO, a therapeutic assistance robot designed in the form of a baby seal, in the management of pain during peripheral intravenous catheterization in children. The investigators will compare the effects of PARO in combination with standard care versus standard care alone during needle-related procedures. The primary objective is to determine whether the use of this device improves pain management in children undergoing skin puncture.\n\nThis study is designed as a multicenter, randomized, open-label, superiority trial conducted across five pediatric centers. A total of 120 infants and children aged 12 months to 7 years undergoing peripheral intravenous catheterization will be enrolled. Pain will be assessed using the FLACC (Face, Legs, Activity, Cry, Consolability) observational scale, which is validated for this age group.\n\nSecondary objectives include the assessment and comparison of procedural distress between groups using the PRIC (Procedural Restraint Intensity in Children) score, evaluation of heart rate variability, number of catheterization attempts, parental anxiety measured by the STAI (State-Trait Anxiety Inventory), and satisfaction levels among both parents and healthcare staff.",[29],[94],"pediatric",{"date":40,"type":41},{"date":97,"type":41},"2026-03-03",{"date":99,"type":23},"2027-03-30",{"name":101,"class":47},"Fondation Lenval",5,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":48},"100595462","assessment-of-morbidity-and-mortality-following-serratus-anterior-plane-block-sapb-for-unilateral-rib-fractures-100595462","NCT07032766","Assessment of Morbidity and Mortality Following Serratus Anterior Plane Block (SAPB) for Unilateral Rib Fractures","SAPB","Inclusion Criteria:\n\n* Patients over 18 years of age being treated in the Emergency Department at Jacobi Medical Center\n* Presenting within 24 hours of injury\n* Patient with 2 or more unilateral, anterior or lateral rib fractures\n* Able to provide consent (patient or health care proxy)\n* Clinical team believes the patient will require inpatient admission at the time of enrollment\n\nExclusion Criteria:\n\n* Patients in traumatic arrest or hemodynamic instability\n* Patient expected to be discharged from the hospital within 24 hours\n* Prisoner\n* Pregnancy\n* Children less than 18 years of age\n* The patient is known or is suspected to be allergic to anesthetic\n* Significant pain from another traumatic and distracting injury\n* Patients without the ability to consent (or no health care proxy to consent)\n* Patients with bilateral or posterior rib fractures",{"count":111,"type":23},220,"OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of the serratus anterior plane block (SAPB) in adult patients who suffered multiple unilateral anterolateral rib fractures within 24 hours of patient presentation to the emergency department. The main question it aims to answer is:\n\nDoes the SAPB for multiple anterolateral rib fractures demonstrate reduction in patient morbidity and mortality, including incidence of pneumonia, length of hospital stay, discharge disposition, and death, as compared to standard analgesic regimens.\n\nThe SAPB will be performed if a physician trained in the SAPB is available within 24 hours of injury. If a trained physician is not available and the patient meets inclusion criteria, they will receive parental analgesia with opioid therapy. They will be followed until date of hospital discharge, up until 60 days.",[29,115,116],"Rib Fracture Multiple","Serratus Anterior Plane Block",[118,119,120,121],"serratus anterior plane block","rib fractures","mortality","morbidity","2026-08-17",{"date":38,"type":41},{"date":125,"type":41},"2025-08-10",{"date":127,"type":23},"2027-07",{"name":129,"class":47},"Albert Einstein College of Medicine",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":18,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":48},"100652187","distraction-methods-for-reducing-pain-and-fear-during-blood-draw-in-children-100652187","NCT07770191","Distraction Methods for Reducing Pain and Fear During Blood Draw in Children","Effects of Pinwheel Blowing, 3D Hologram Viewing, and Gum Chewing on Pain and Fear During Blood Draw in Children: A Randomized Controlled Trial","PED-DISTRACT","Inclusion Criteria:\n\n* Children aged 5 to 10 years\n* Scheduled to undergo a blood draw\n* No analgesic medication use within 6 hours before the procedure\n* No visual, hearing, or speech impairment\n* No neurological disorder\n* No oral or jaw condition that may prevent gum chewing\n* No chronic illness requiring frequent invasive procedures\n* Written informed consent provided by the parent or legal guardian\n* Verbal assent provided by the children\n\nExclusion Criteria:\n\n* Previous history of syncope during blood draw procedures\n* Blood draw not completed on the first attempt\n* Development of syncope during the procedure\n* Inability or unwillingness to complete the assigned intervention\n* Withdrawal of consent or assent by the parent or child at any stage of the study",true,"5 Years","10 Years",{"count":142,"type":23},164,[26],"Blood draw is a common invasive procedure that can cause pain and fear in children. This randomized controlled trial aims to compare the effects of pinwheel blowing, 3D hologram viewing, and sugar-free gum chewing on pain and fear during blood draw among children aged 5-10 years. Parental satisfaction with the care provided during the procedure will also be evaluated.\n\nA total of 164 children will be assigned in a 1:1:1:1 ratio to the pinwheel blowing, 3D hologram viewing, gum chewing, or control group using block randomization stratified by age and sex. The interventions will begin one minute before the blood draw and continue until the procedure is completed. Children in the control group will receive the routine blood draw procedure without any additional nonpharmacological intervention.\n\nImmediately after the blood draw, the child's pain and fear during the procedure will be independently evaluated by the child, the accompanying parent, and an independent observer nurse. Parental satisfaction will also be assessed after the procedure.",[29,146],"Fear",[148,149,150],"Distraction","3D Hologram","Gum Chewing","2026-08-14",{"date":70,"type":41},{"date":154,"type":41},"2026-06-15",{"date":156,"type":23},"2026-09-15",{"name":158,"class":159},"Gülsev Kutman","OTHER_GOV",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":48},"100651840","pcdd-generation-1-oral-liquid-acetaminophen-delivery-evaluation-100651840","NCT07765238","PCDD Generation 1 Oral Liquid Acetaminophen Delivery Evaluation","Evaluation of the Patient-Controlled Dispenser & Deactivator (PCDD) Generation 1 System for Oral Liquid Acetaminophen Delivery","Inclusion Criteria:\n\nParticipants\n\n* Admitted to the participating orthopedic service for elective total shoulder replacement\n* Received a preoperative brachial plexus block\n* English speaking - as on-site study members are only fluent in English\n* Able to independently use the PCDD system and follow basic operating instructions\n\nNurses\n\n* Registered nurse employed at Yale New Haven Hospital.\n* Provides clinical care to an enrolled study participant during the participant's hospitalization.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\nParticipants\n\n* Patient refusal to participate\n* Pregnancy: all child bearing age patients will receive a urine screening test on the day of surgery and this result will be documented in the EMR epic. This is an elective procedure and the surgery will almost always be cancelled in the case of positive pregnancy test. In the extremely rare event the care proceeds, we will exclude the patient from the study. Emergency surgery\n* Cognitive impairment preventing informed consent or independent use of the device\n* Chronic pain requiring ongoing pain management or home opioid use\n* Substance use disorder\n* Failed preoperative brachial plexus block, defined as significant postoperative pain in the PACU requiring early escalation of analgesic management\n\nNurses\n\n* Declines or is unwilling to provide informed consent.",{"count":168,"type":23},60,[26],"This prospective randomized pilot study evaluates the feasibility, acceptability, and preliminary efficacy of the Patient-Controlled Dispenser and Deactivator (PCDD) Generation 1 system for patient-controlled oral liquid acetaminophen administration in postoperative total shoulder replacement inpatients compared with standard nurse-administered oral acetaminophen delivery.",[29,172],"Postoperative Pain",[174],"total shoulder replacement surgery","2026-08-10",{"date":151,"type":41},{"date":178,"type":23},"2026-08",{"date":75,"type":23},{"name":181,"class":47},"Yale University",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":206,"locationsCount":48},"100628877","phase-3-anterior-iliopsoas-space-block-versus-peng-block-on-ease-of-positioning-for-spinal-anathesia-in-patients-undergoing-hip-surgeries-100628877","NCT07467356","Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries","Impact of Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries ;Randomized Clinical Trial","Inclusion Criteria:\n\n* (ASA )classes I and II\n* patients of either sex, above the age of 18 who will undergo hip surgeries( (Dynamic hip screw fixation or hemiarthroplasty)(not older than 2 weeks) with persistent pain and scheduled for surgery under SA with an expected duration of 2.5 hours\n\nExclusion Criteria:\n\n* patient's refusal to participate\n* any contraindications to SA or peripheral nerve blocks\n* history of ischemic heart disease\n* patients on opioids for chronic pain\n* patients with significant cognitive impairment.",{"count":190,"type":23},90,[192],"PHASE3","Total hip arthroplasty (THA) has been one of the most significant advancements in orthopedic surgery over the past century. hip fractures are typically associated with severe pain, effective analgesia is crucial both before and after surgery.Spinal anesthesia (SA) is the most commonly employed method of anesthesia for repairing these fractures.The anterior iliopsoas space block is a considered as a novel technique that targets the lumbosacral trunk as it passes beneath the psoas major muscle, offering potential advantages over the traditional sacral plexus block, which is performed in the supine position.",[29],[196,197,198,199],"PENG block","anterior iliopsoas space block","ease of positioning","hip surgeries","2026-08-09",{"date":202,"type":41},"2026-08-11",{"date":204,"type":41},"2026-03-15",{"date":156,"type":23},{"name":207,"class":47},"Benha University",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100651344","turkish-version-of-the-pictorial-pain-interference-questionnaire-100651344","NCT07761208","Turkish Version of the Pictorial Pain Interference Questionnaire","Assessment of the Functional Impact of Chronic Pain: Psychometric Properties of the Turkish Version of the Pictorial Pain Interference Questionnaire","Inclusion Criteria:\n\n* Having chronic pain lasting for at least 3 months.\n* Willing to participate in the study and providing informed consent.\n* Having sufficient cognitive ability to understand the questions.\n\nExclusion Criteria:\n\n* Severe cognitive impairment (e.g., dementia) or conditions that interfere with communication.\n* Inability to cooperate due to a psychiatric disorder.\n* Neurological or serious systemic diseases that may affect the assessment.\n* Incomplete or incorrectly completed questionnaires.\n* Refusal to participate or withdrawal from the study.",{"count":216,"type":23},100,"This study aims to culturally adapt the Pictorial Pain Interference Questionnaire into Turkish and evaluate its psychometric properties in individuals with chronic pain. The study will assess the validity and reliability of the Turkish version for evaluating the functional impact of chronic pain on daily life activities. Reliability will be examined through internal consistency and test-retest reliability, while validity will be assessed by examining the relationships between the questionnaire and established pain-related assessment tools. The study will determine whether the Turkish version provides a valid, reliable, and practical instrument for assessing functional interference associated with chronic pain in Turkish-speaking individuals.",[62,29],[63,220,221,222,223],"Pain Interference","Pictorial Pain Interference Questionnaire","Psychometric Properties","Turkish Version","2026-08-08",{"date":226,"type":41},"2026-08-12",{"date":40,"type":23},{"date":229,"type":23},"2027-02-22",{"name":231,"class":47},"Istinye University",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":48},"100651589","phase-3-safinamide-vs-placebo-for-pain-in-patients-with-parkinsons-disease-and-motor-fluctuations-100651589","NCT07761936","Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations","Effects of Safinamide Versus Placebo on Pain in Patients With Parkinson's Disease With Motor Fluctuations: A Randomized, Controlled, Double-Blind Clinical Trial","SAVE PAIN","Inclusion Criteria:\n\n* Age ≥ 18 years; PD-related chronic pain (lasting more than 3 months) and motor fluctuations while receiving stable doses of L-dopa (alone or with other dopaminergic treatments) for at least 4 weeks prior to baseline (visit T0).\n* Diagnosis of PD according to the International Parkinson and Movement Disorders Society (MDS) clinical diagnostic criteria.\n* Disease duration since diagnosis of ≥ 3 years.\n* Presence of motor fluctuations (\\> 1.5 hours OFF time\u002Fday excluding morning akinesia)\n* Hoehn and Yahr stage II-III during ON time.\n* A history of pain symptoms for the last 12 weeks \\[at least 4 points scored on the Numerical Rating Scale (NRS)\\].\n* Willing to participate in this study and able to understand and sign the written informed consent and the form privacy data.\n* Be responsive to levodopa as per the MDS Clinical Diagnostic Criteria for Parkinson's disease, which define responsiveness as a clinically meaningful benefit to dopaminergic therapy, either documented objectively or subjectively.\n* Be on stable daily doses of oral L-dopa (including controlled release \\[CR\\], immediate release \\[IR\\] or a combination of CR\u002FIR), with and without benserazide\u002Fcarbidopa, and optionally with a catechol-O-methyltransferase (COMT) inhibitor. Participants may also be receiving stable doses of dopamine agonists, anticholinergics and\u002For amantadine for at least 4 weeks prior to the screening visit.\n* Participants must be able to speak and understand the Italian language.\n* If female, participants must either be post-menopausal for at least one year, as self-reported by the patient, or, if of childbearing potential, must have a negative plasma human chorionic gonadotropin (HCG) test to exclude pregnancy at screening. Additionally, if of childbearing potential, patients will be required to undergo monthly urine pregnancy testing, scheduled at approximately day 30 and day 60, and the urine test at the final visit (T1). Moreover, women of childbearing potential must agree to use a highly effective method of contraception, starting 2 months before enrollment, throughout the entire duration of the study and for at least 30 days after the last dose of the study medication. Acceptable methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence \\[Sexual abstinence is considered an acceptable method only if it reflects the participant's consistent and preferred lifestyle.\\].\n\nExclusion Criteria:\n\n* Concomitant therapy with monoamine oxidase B inhibitors.\n* Patients experiencing severe, disabling peak-dose or biphasic dyskinesia, or unpredictable or widely swinging symptom fluctuations.\n* De novo patients.\n* Evidence of dementia suggested by a Mini-Mental Scale Examination (MMSE) score \\\u003C 24.\n* Evidence of depression according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, DSM V.3.\n* Treatment with antidepressant medications.\n* Signs and symptoms suggestive of atypical parkinsonism.\n* Severe and progressive medical illnesses other than PD.\n* Concomitant diseases potentially causing acute or chronic pain (i.e., rheumatologic conditions, cancer, severe polyneuropathy, and spine injuries).\n* Treatment with opioids, neuroleptics, barbiturates, phenothiazines, pregabalin, gabapentin.\n* Any other contraindication according to the current Summary of product characteristics (SmPC) of safinamide.\n* Previous neurosurgical intervention or stereotactic brain surgery for PD.\n* Concomitant infusive device-aided therapies for PD.\n* Drug and\u002For alcohol abuse within 12 months prior to the screening visit.\n* Use of any investigational drug or device within 30 days prior to screening or 5 half-lives (whichever is the longest), or at any point during the study.\n* Known allergy, sensitivity, or contraindications to the investigational medicinal products (IMPs), their excipients.\n* Any clinically significant condition which, in the opinion of the Investigator, would be incompatible with study participation or pose a risk to the patient during the study.\n* Moderate to severe liver failure as defined by the Child-Pugh classification score, or human immunodeficiency virus (HIV) infection.\n* Treatment with monoamine oxidase inhibitors (MAOIs), pethidine, opiates, opioids, fluoxetine, fluvoxamine within 4 weeks prior to the screening visit. These drugs are not allowed throughout the study and up 2 weeks after the last dose of study drug.\n* History of ophthalmologic conditions including any of the following: albinism, uveitis, retinitis pigmentosa, retinal degeneration, active retinopathy, severe progressive diabetic retinopathy, inherited retinopathy or family history of hereditary retinal disease.\n* Pregnancy and breastfeeding.",{"count":168,"type":23},[192],"This is a Phase III, single-center, randomized, double-blind, placebo-controlled clinical trial designed to investigate the superiority of safinamide compared to a placebo in reducing Parkinson's Disease (PD)-related pain.\n\nThe trial plans to enroll 60 adult patients diagnosed with PD who experience motor fluctuations and chronic pain (lasting more than 3 months) despite receiving stable doses of levodopa.\n\nParticipants will be randomized in a 1:1 ratio to receive either oral safinamide or a matching placebo as an add-on therapy. The treatment regimen consists of 50 mg\u002Fday for the first week, increasing to 100 mg\u002Fday for the remaining 11 weeks, for a total treatment duration of 12 weeks.\n\nThe primary endpoint is to evaluate the mean change in pain severity from baseline to 12 weeks, measured using the 11-point Numeric Rating Scale (NRS) Secondary endpoints will assess additional qualitative and quantitative pain characteristics (KPPS, BPI, PD-PCS), motor symptoms and treatment complications (UPDRS Parts III and IV, Home Diary), quality of life (PDQ-39), and other non-motor symptoms (MDS-NMS).\n\nThe total expected duration of the clinical trial is 24 months.",[244,62,29,245],"PARKINSON DISEASE (Disorder)","Parkinson Disease (PD)","2026-08-07",{"date":248,"type":41},"2026-08-13",{"date":250,"type":41},"2026-04-28",{"date":75,"type":23},{"name":253,"class":47},"Universita di Verona",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":24,"phases":263,"briefSummary":264,"conditions":265,"keywords":270,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":286},"100651005","clinical-assessment-and-treatment-in-the-nursing-home-as-an-alternative-to-hospital-admission-100651005","NCT07756554","Clinical Assessment and Treatment in the Nursing Home as an Alternative to Hospital Admission","Home-Based Assessment and Treatment by Municipal Acute Care Teams Combined With Remote Senior Physician Consultation as an Alternative to Hospital Admission for Nursing Home Residents: A Multicenter Randomized Controlled Trial","Clusters (Nursing Homes):\n\nInclusion Criteria:\n\n* Nursing homes, defined as long-term care facilities with care personnal available 24\u002F7 for residents with need for continued medical care\n* Nursing homes located in the Capital Region of Denmark\n* Nursing homes accepting participation and cluster randomization\n\nExclusion criteria\n\n* Assisted living facilities, intermediate\u002Ftemporary care units, rehabilitation units, hospices, or other non-nursing-home setting.\n* Nursing homes located on the island of Bornholm",{"count":262,"type":23},9000,[26],"This multicenter, cluster-randomized, unblinded quality-improvement study evaluates whether home-based clinical assessment by municipal acute care teams can safely reduce hospital admissions among nursing home residents experiencing acute illness or clinical deterioration during out-of-hours periods. Participating nursing homes in the Capital Region of Denmark will be randomized to either usual care (contacting the regional medical helpline, 1813) or the intervention pathway, in which nursing home staff contact a municipal acute care team directly. The acute care team performs an on-site clinical assessment and, when needed, consults a senior physician in the hospital emergency department to establish a treatment and observation plan, which may include continued management at the nursing home under hospital responsibility. The study compares the intervention with usual care with respect to hospital admissions and mortality among nursing home residents.",[266,267,268,269,29],"Nursing Homes Residents","Deterioration, Clinical","Infection","Dehydration",[271,272,273,274,275,276,277,278],"hospital at home","admission avoidance","home-based treatment","nursing home residents","Hospital-at-Home","HaH","HITH","Hospital in the home","2026-08-06",{"date":175,"type":41},{"date":282,"type":41},"2026-02-01",{"date":75,"type":23},{"name":285,"class":47},"Copenhagen University Hospital at Herlev",4,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":24,"phases":296,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":308,"locationsCount":48},"100650218","ultrasound-guided-recto-intercostal-fascial-plane-block-in-laparoscopic-cholecystectomy-100650218","NCT07745972","Ultrasound-Guided Recto-Intercostal Fascial Plane Block in Laparoscopic Cholecystectomy","Evaluation of the Effect of Ultrasound-Guided Bilateral Recto-Intercostal Fascial Plane Block on Postoperative Pain, Opioid Consumption, and Quality of Recovery in Laparoscopic Cholecystectomy Surgery: A Prospective, Randomized, Double-Blind Controlled Clinical Study","Inclusion Criteria:\n\n* BMI \\\u003C 35 kg\u002Fm²\n* Patients with ASA scores I and II\n\nExclusion Criteria:\n\n* Patients who do not want to be included in the study\n* Psychiatric and neurological disease with blurred consciousness\n* Patients with ASA \\> 3\n* BMI \\> 35 kg\u002Fm²\n* Abnormality in coagulation parameters\n* History of allergy to local anesthetic drugs\n* Infection at the injection site","80 Years",{"count":168,"type":23},[26],"The aim of the study is to reduce postoperative pain by performing rectointercostal block in L\u002FS cholecystectomy surgeries. Main goal is to provide well managed post-operative analgesia.",[299,29,300],"Analgesia","Pain, Acute Post-Operative",[302,303,172],"Cholesistectomy","Rectointercostal Plane Block",{"date":175,"type":41},{"date":279,"type":41},{"date":307,"type":23},"2026-12-31",{"name":231,"class":47},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":316,"enrollmentInfo":317,"targetDuration":4,"studyType":24,"phases":318,"briefSummary":319,"conditions":320,"keywords":325,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":331,"leadSponsor":333,"locationsCount":48},"100649786","anterior-suprascapular-and-axillary-vs-interscalene-block-for-analgesia-and-diaphragmatic-function-in-shoulder-surgery-100649786","NCT07739303","Anterior Suprascapular and Axillary vs. Interscalene Block for Analgesia and Diaphragmatic Function in Shoulder Surgery","Comparison of Anterior Suprascapular and Axillary Nerve Block Versus Interscalene Block for Postoperative Analgesia and Diaphragmatic Function in Shoulder Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years\n* American Society of Anesthesiologists (ASA) physical status I, II, or III\n* Patients scheduled to undergo elective arthroscopic shoulder surgery\n* BMI between 18 and 30 kg\u002Fm2\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to local anesthetics\n* Presence of localized infection at the planned injection site\n* Severe coagulopathy or active use of anticoagulant medications\n* Contralateral phrenic nerve palsy or a diagnosis of severe chronic obstructive pulmonary disease (COPD)\n* History of chronic opioid consumption or neuropathic pain","65 Years",{"count":57,"type":23},[26],"Shoulder surgeries are among the most frequently performed orthopedic interventions and are often associated with moderate to severe postoperative pain. In these procedures, effective pain management is crucial for early rehabilitation and patient comfort.\n\nPeripheral nerve blockade is widely used for postoperative analgesia in shoulder surgery. While the interscalene brachial plexus block is considered the gold standard for pain control, it is frequently associated with unintended phrenic nerve blockade, leading to hemidiaphragmatic paresis. To minimize respiratory complications while maintaining effective analgesia, alternative diaphragm-sparing regional anesthesia techniques, such as the combination of suprascapular and axillary nerve blocks, have been introduced.\n\nThe aim of this study is to compare the analgesic efficacy and respiratory functions preservation of the ultrasound-guided anterior approach suprascapular combined with axillary nerve block versus interscalene block in patients undergoing shoulder surgery",[321,29,322,323,324],"Peripheral Nerve Block","Diaphragm Protective Block","Upper Extremity","Interscalene Block",[326,324,327,328,29],"Shoulder Arthroscopy","Anterior Suprascapular Block","Axillary Block",{"date":246,"type":41},{"date":279,"type":41},{"date":332,"type":23},"2026-12-28",{"name":334,"class":159},"Ankara Etlik City Hospital",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":138,"sex":18,"minAge":343,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":346,"conditions":347,"keywords":353,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":367},"100633235","giving-children-a-voice-in-paediatric-anaesthesia-100633235","NCT07524049","Giving Children a Voice in Paediatric Anaesthesia","Patient, Parent and Clinician Voices - Establishing National and International Research Priorities for Paediatric Anaesthesia and Perioperative Medicine","TR-VP26","Inclusion Criteria:\n\n* Patients aged 6-16 years\n* Caregivers of patients aged 6-16 years\n* Clinicians working in paediatric perioperative medicine\n\nExclusion Criteria:\n\n* Patients \\\u003C6 and \\>16 years\n* Residence not in Switzerland\n* Inability to understand one of the 3 study languages (german, french, italian)","6 Years",{"count":345,"type":23},1040,"This project will identify the research priorities for paediatric anaesthesia and perioperative medicine in participating countries and highlight areas where further research and information can be provided to optimise the experience of children undergoing medical interventions.\n\nThis is expected to have significant positive impacts on patient and family engagement and interest in research within the community and aids to plan patient\u002F family-centred studies.",[348,349,29,350,351,352],"Perioperative Care","Pediatric Anesthesia","Anxiety","Research Agenda","Research Subjects",[354,355,356,357,358,359],"perioperative medicine","pediatric anesthesia","patient perspective","parent perspective","research priorities","survey",{"date":202,"type":41},{"date":362,"type":41},"2026-05-27",{"date":364,"type":23},"2027-12-31",{"name":366,"class":47},"Insel Gruppe AG, University Hospital Bern",7,{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":375,"maxAge":316,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":392,"leadSponsor":394,"locationsCount":48},"100624222","phase-1-psilocybin-after-trauma-surgery-for-pain-100624222","NCT07406828","Psilocybin After Trauma Surgery for Pain","Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder","Inclusion Criteria:\n\n1. ≥ 25 years old and ≤65 years old\n2. Inpatient\n3. English-speaking\n4. History of opioid use disorder as diagnosed by DSM-V\n5. Able to swallow capsules.\n6. Patients are able to be enrolled and receive psilocybin within 3 days (72 hours) of surgery (time point 0 for this three-day window begins after patient arrival in the ICU) after a trauma surgery. Psilocybin will be administered in the morning to allow for the 8-hour monitoring period.\n\nExclusion Criteria:\n\n1. Pregnancy. Women of child-bearing potential need to have a negative pregnancy test result at screening and baseline.\n2. Sexually active male participants and\u002For their female partners and female participants of child-bearing potential need to be on adequate and effective method of contraception (diaphragm, male condom, combined pill, copper IUD, levonorgestrel IUS, etonogestrel implant).for one week following study drug administration.\n3. Breastfeeding\n4. Patients receiving concurrent ketamine therapy or who have received ketamine therapy during the trauma admission.\n5. UDS screen on admission (if obtained) positive for alcohol, opioids other than prescribed for pain or maintenance opioids for OUD, or other substances of abuse\n6. History of psychedelic substance use in the preceding 5 years\n7. History (or active) cardiovascular disease (non-optimized coronary vascular disease, stable or unstable angina, new onset EKG abnormalities, congenital long QT syndrome, cardiac trauma involving surgical repair or CABG within 1 year)\n8. Screening blood pressure SBP \\>140 mmHg or DBP \\> 90 mmHg on three separate occasions\n9. Head trauma, traumatic brain injury, or concussion.\n10. Tachycardia defined as HR \\> 100, averaged over the previous 12 hours, excluding intra-operative care)\n11. History of dementia\n12. History of pre-existing neurological conditions (including TIA, stroke, epilepsy, MS, ALS, Guillain-Barre, Parkinson's)\n13. Patients on SSRIs, TCAs, MAO-Is, lithium, or other serotonergic medications, antipsychotics. Prohibited medications need to be discontinued at least 30 days prior to psilocybin dosing.\n14. Patients that received intra-operative intravenous methadone dosing \\> 20 mg.\n15. On vasopressors\n16. Hepatic impairment, mild to moderate, with Child-Pugh score ≥ 7\n17. Nicotine dependence, which would prevent the patient from staying in their room for the duration of the 8-hour psilocybin study period.\n18. On sedating IV infusions (propofol, ketamine, fentanyl, benzodiazepine, dexmedetomidine)\n19. History of suicidal or homicidal ideations within the last year\n20. History of seizure disorder\n21. Requiring restraints or active sitter\n22. Patients with a history of poorly controlled anxiety (GAD7 score of 10 or more), poorly controlled depression (PHQ9 score of 15 or more), panic disorder, paranoia, PTSD, bipolar disorder, any primary psychotic disorder like schizophrenia, schizoaffective disorder, or antisocial personality disorder; personal or first- or second-degree relative history of psychotic or bipolar I or II disorder\n23. History of Hallucinogen Use Disorder or Hallucinogen Persisting Perception Disorder (per DSM-V)\n24. Unable to consent (intubated\u002Fsedated)\n25. Intellectual disability\n26. Additional or anticipated surgeries within 7248 hrs of psilocybin administration\n27. Discharge from hospital pending within 24 hrs of psilocybin administration\n28. Any allergy to psilocybin or other inert substances in the product","25 Years",{"count":57,"type":23},[378],"PHASE1","The goal of this clinical trial is to evaluate whether a single dose of psilocybin is feasible and safe for adults with opioid use disorder (OUD) who are recovering from trauma surgery. The main questions it aims to answer are:\n\n1. Is a single psilocybin dose feasible to administer during postoperative hospitalization?\n2. Is psilocybin safe in this patient population?\n3. How does psilocybin affect postoperative pain, opioid use, anxiety, and depression after hospital discharge?\n\nParticipants will:\n\nReceive one oral dose of psilocybin during their postoperative inpatient stay Complete assessments of pain, mood, and opioid use during recovery",[29,172],[382,383,384,385,386,387,388],"psilocybin","postoperative trauma","opioid","opioid use prevention","surgery","mushrooms","opioid adverse events","2026-08-05",{"date":279,"type":41},{"date":364,"type":23},{"date":393,"type":23},"2029-08",{"name":395,"class":47},"Trent Emerick",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":18,"minAge":404,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":408,"briefSummary":409,"conditions":410,"keywords":413,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":48},"100611083","new-therapeutic-interventions-and-imaging-techniques-for-prolonged-shoulder-disorders-100611083","NCT07235969","New Therapeutic Interventions and Imaging Techniques for Prolonged Shoulder Disorders","Effectiveness of Psychologically Informed Physical Therapy, Tendon-specific Exercise Program and Routine Physical Therapy in Prolonged Unilateral Shoulder Pain and Symptom Correlations With Imaging: a Single-center, Randomized, Parallel-group, Three-arm Study (RESPECT)","RESPECT","Inclusion Criteria:\n\n* Age of 20-60 years\n* Active participation in the workforce (employed or entrepreneur)\n* Active occupational health care services available\n* Daily unilateral shoulder pain for at least four consecutive weeks\n* Willingness to participate in independent rehabilitation and PT visits\n\nExclusion Criteria:\n\n* Bilateral shoulder pain\n* Previous humerus fracture or current acute upper limb injury\n* Prolonged dysfunction or pain of the upper limb attributable to trauma, neurologic disease or cervical spine disorders\n* Diagnosed musculoskeletal disorders affecting the upper limb (e.g. rheumatoid arthritis)\n* Severe disability, mental or memory disorder\n* Advanced cancer\n* History of shoulder PT or corticosteroid injection in the last six months\n* Previous or planned shoulder surgery\n* Confirmed or possible pregnancy\n* Contraindications to MRI\n* Severe chronic kidney disease\n* Evidence unaccounted malignancy or other exclusionary findings in the initial eligibility assessment on either side","20 Years","60 Years",{"count":407,"type":23},300,[26],"The RESPECT study compares three types of physical therapy for adults aged 20-60 years with prolonged shoulder disorders, aiming to find better ways to help people recover and improve daily function. The study also examines modern imaging tests (X-ray, ultrasound, MRI) to see how well imaging findings match real symptoms, and tests new imaging technologies that may provide a more accurate diagnosis. The study improves future shoulder pain care by addressing both physical and psychological factors and advancing diagnostic imaging.\n\nParticipants are randomly assigned to one of three groups:\n\n1. Routine physical therapy (usual occupational care),\n2. Tendon-Specific Exercise Program (TSEP): targeted exercises to build shoulder strength and\n3. Psychologically Informed Physical Therapy (PIPT): combining physical rehabilitation with advice and emotional support.\n\nAll participants get complete imaging of both shoulders and a clinical evaluation by a physiotherapist at the start of the study. Complete imaging is also done for all participants after twelve and thirty-six months. Surveys about pain, movement, mood, sleep, and quality of life are collected electronically at the start of the study, and at three, six, twelve, and 36 months. The main outcome is how well each person resumes everyday activities affected by shoulder pain (Patient-Specific Functional Scale, PSFS).\n\nGroup 1 will receive routine occupationally led physiotherapy, and groups 2 and 3 will receive five physiotherapist-guided sessions during the first six month-period. Advanced imaging techniques will deployed in conjunction with standard imaging methods and compared to see whether new technologies help explain symptoms or guide care.\n\nTo join, participants must have had prolonged shoulder disorders in one shoulder for at least four consecutive weeks, be employed or self-employed, and be willing to take part in rehabilitation activities. Certain medical conditions, prior surgery, and pregnancy are exclusion criteria. Inclusion and exclusion criteria are systematically reviewed in a structured phone interview at the start of the study. Baseline imaging is also viewed preliminarily for certain conditions which would require urgent medical care. If necessary, participants are contacted, informed and subsequently excluded from the study.\n\nThe trial takes place at Oulu University Hospital, Finland. Approximately 300 people are recruited to the study through local occupational health care providers. Informed consent is required for the study, and participants can withdraw at any time. All procedures meet ethical standards.\n\nThis study will help determine:\n\n1. Which therapy works best overall\n2. Whether some people benefit more from certain therapies\n3. If imaging findings help predict outcomes or aid treatment decisions\n4. Whether new imaging technology improves diagnosis",[411,29,412],"Shoulder Pain","Physical Therapy",[29,414,415,416,417,418,419],"Psychologically Informed Physical Therapy","Magnetic resonance fingerprinting","Diagnostic Imaging","Microvascular Flow Imaging","Tendon-Specific Exercise Program","Shear Wave Elastography",{"date":175,"type":41},{"date":422,"type":23},"2026-09",{"date":424,"type":23},"2030-09",{"name":426,"class":47},"University of Oulu",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":433,"maxAge":316,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":442,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":447,"leadSponsor":449,"locationsCount":4},"100650553","photobiomodulation-therapy-for-pain-control-in-post-operative-total-knee-arthroplasty-patients-a-pilot-study-100650553","NCT07750912","Photobiomodulation Therapy for Pain Control in Post-Operative Total Knee Arthroplasty Patients: A Pilot Study","Inclusion Criteria:\n\nBMI less than or equal to 45\n\nCurrently set up for an elective primary total knee arthroplasty due to primary osteoarthritis\n\nAbility to provide informed consent to participate in the clinical trial\n\nAbility to understand and communicate in English\n\nWillingness to comply with all study procedures\n\nExclusion Criteria:\n\n* poorly controlled comorbidities that would not allow surgical intervention such as poorly controlled diabetes (HbA1C \\> 8.0) renal insufficiency (eGFR \\\u003C60) poorly controlled CV disease such as CHF that is NYHA class 3 and 4\n* inability to receive the intervention including contraindications and\u002For known photosensitivity.\n* patients with history of total joint infection ever or any infection in the last 6 months\n* ASA score \\>3 and Outpatient Arthroplasty Risk Assessment (OARA; medical risk stratification scoring system to help determine day surgery vs inpatient)1 score \\> 80.\n* previous PBMT treatment within 3 months from the start of the study for the participant.\n* utilization of supplemental\u002Fholistic methods specifically for pain control (e.g. cannabidiol). This will be discontinued 30 days prior to TKA and will not be used during the duration of study participation. This will be evaluated by the Principal Investigator and study team prior to consent.\n* significant anti-coagulation usage (other than aspirin) 7 days prior to treatment\n* CV surgery within the last 6 months\n* significant neurologic compromise (acquired or congenital\u002Fgenetic) of the lower extremity to be operated on or underlying neurologic condition that would confound results in the opinion of the investigator such as a previous brachial plexus injury after a motor vehicle accident or myasthenia gravis\n* regular opioid use prior to surgical intervention as defined as \\>20 MME per day for 30 days prior to enrollment.\n* Intolerance\u002Fallergy to hydrocodone or codeine\n* significant physical deformity of the planned operative extremity that would confound the results in the opinion of the investigator(s)\n* Immunocompromised patients, that in the opinion of the investigators, would confound the patient's ability to heal such as rheumatoid arthritis patient taking immunosuppressants.\n* females who are pregnant or who are expecting to be pregnant for the duration of the study\n* any tattoos or other permanent markings located on the treatment area\n\nMale patients or female who are not pregnant and do not plan on future pregnancy during trial participation, between 30-65 years of age\n\nExclusion Criteria:\n\n\\-","30 Years",{"count":435,"type":23},15,[26],"A pilot study to assess the efficacy and feasibility of PBMT for pain control in patients undergoing a TKA and are discharged the same day from an ambulatory surgery center.",[29,439,440,441],"TKA","Post Operative Analgesia","Low Level Laser Therapy",[441,443,439],"Post operative pain control","2026-08-03",{"date":279,"type":41},{"date":178,"type":23},{"date":448,"type":23},"2028-07",{"name":450,"class":47},"Mohammad Burney, MD",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":24,"phases":459,"briefSummary":461,"conditions":462,"keywords":467,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":472,"locationsCount":48},"100516225","phase-2-psilocybin-in-cancer-pain-study-100516225","NCT06001749","Psilocybin in Cancer Pain Study","Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer","Inclusion Criteria:\n\n* Participants must be 18 year old or older;\n* Participants must have advanced cancer, defined as a cancer that is unlikely to be cured or controlled with treatment;\n* Participants must have progressed on or be intolerant to approved therapies with a known clinical benefit (unless it is documented that they have refused such treatments);\n* Participants must evaluate their average pain on BPI Severity Scale ≥ 4\u002F10 over the past week;\n* Participants must receive chronic opioid pharmacotherapy for pain with an Oral Morphine Equivalent (OME) ≥ 200mg\u002Fday;\n* Participants must have been seen by a palliative care clinician either at DFCI, MGH or associated satellites in the last three months;\n* Participants must have an ECOG Performance Status ≤ 2\n* Participants must meet the following organ and marrow function on their last available bloodwork as defined below:\n\n  * Platelets ≥ 50,000\u002FmcL\n  * AST(SGOT)\u002FALT(SGPT) ≤ 5 × institutional ULN\n* Participants must be able to understand and willing to sign a written informed consent document\n* Participants must be able to swallow pills.\n* Participants must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.\n* Participants must agree to inform the investigators within 48 hours of any new medical conditions and procedures.\n* Participants must agree to the following lifestyle modifications (described in more detail in Section 3.4 Lifestyle Modifications):\n\n  * Comply with requirements for diet,\n  * Refrain from certain medications prior to Experimental Sessions,\n  * Be driven home after each Experimental Session,\n  * Commit to medication dosing, therapy, and study procedures.\n\nExclusion Criteria:\n\n* Participants who receive concurrent (less than four weeks or planned within 6 weeks) cytotoxic chemotherapy or radiation therapy that may impair general level of physical functioning or affect study outcomes;\n* Participants with a condition impairing oral intake or digestive absorption;\n* Participants who are not able to give adequate informed consent;\n* Participants who have a significant suicide risk as defined by suicidal ideation with intent and with or without a plan as endorsed on items 4 and\u002For 5 on the C-SSRS within the past 6 months or at V0\n* Participants who have a history of, or a current diagnostic of primary psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1 or history of or current dissociative identity disorder; and participants who have an ongoing substance use disorder (defined as active in the past year). Participants with first-degree relatives with schizophrenia or bipolar disorder may be eligible depending on their age and personal and family psychiatric history. The decision will be made by the principal investigator and study psychiatrist based on risk assessment.\n* Participants for whom there is a potential for adverse drug-drug interactions. Concomitant medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. These include the following:\n\n  * Serotoninergic antidepressants\n  * Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)\n  * Tricyclic Antidepressants (TCAs)\n  * Efavirenz\n  * serotonin-acting dietary supplements (i.e. 5-hydroxy-tryptophan or St. John's wort)\n  * Centrally-acting serotonergic agents (e.g. MAO inhibitors)\n  * Antipsychotics (e.g. first and second generation)\n  * Mood stabilizers (e.g. lithium, valproic acid)\n  * Aldehyde dehydrogenase inhibitors (e.g. disulfiram)\n  * Significant inhibitors of UGT 1A0 or UGT 1A10 Any psychiatric medication will be tapered if possible in an appropriate fashion to avoid withdrawal effects. They will be discontinued long enough before the psilocybin Session to avoid the possibility of any drug-drug interaction (the interval will be at least five times the particular drug and active metabolites' half-life + one week for stabilization). See section 5.3 of the protocol for concomitant medications and tapering instructions.\n* Participants who have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration (participants with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded).\n* Participants with brain tumors or brain metastases that haven't been successfully treated\n* Participants with lab abnormalities that may contribute to somnolence, confusion or delayed metabolism of psilocybin and\u002For with severe lab abnormalities (grade 3 or more per CTCAE scale).\n* Participants with a diagnosis of cirrhosis or liver failure\n* Participants who have uncontrolled hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher assessed on three separate occasions)\n* Participants who have a heart rate \\> 100 bpm on three separate occasions\n* Participants who have a history of ventricular arrhythmia at any time, other than occasional premature ventricular contractions (PVCs) in the absence of ischemic heart disease.\n* Participants who have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.\n* Participants who have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled if they have been successfully treated.\n* Participants who have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)\n* Participants who have a history of myocardial infarction, coronary artery disease or heart failure\n* Participants who have a marked Baseline prolongation of QT\u002FQTc interval. For purposes of eligibility, this is defined as repeated demonstration of a QT interval corrected on the triplicate ECGs performed at screening, using Fridericia's formula \\[QTcF\\] \\> 450 milliseconds \\[ms\\] in males and \\> 460 ms in females.\n* For transgender or non binary participants, QTc interval will be evaluated based on sex assigned at birth, unless the participant has been on hormonal treatment for five or more years.\n* Women who are pregnant, nursing, or able to become pregnant and are not practicing an effective means of birth control. Acceptable methods of contraception are the following: intrauterine device, injected\u002F implanted\u002F intravaginal\u002F transdermal hormonal method, oral hormones plus a barrier contraception, abstinence, vasectomized sole partner, or double barrier contraception.\n* Participants who have hypersensitivity to any ingredient of the IMP (Investigational Medicinal Product).",{"count":435,"type":23},[460],"PHASE2","The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer.\n\nThe name of the study intervention used in this research study is:\n\nPsilocybin (a tryptamine derivative)",[463,29,464,465,466],"Opioid-Related Disorders","Pain Management and Care","Advanced Cancer","Advanced Cancers",[463,29,464,465,466],{"date":389,"type":41},{"date":470,"type":41},"2024-09-23",{"date":307,"type":23},{"name":473,"class":47},"Yvan Beaussant, MD, MSci",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":139,"maxAge":140,"enrollmentInfo":481,"targetDuration":4,"studyType":24,"phases":482,"briefSummary":483,"conditions":484,"keywords":490,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":496,"leadSponsor":498,"locationsCount":48},"100650603","effect-of-vibration-and-shotblocker-on-pain-and-fear-levels-during-intramuscular-injection-in-children-in-the-emergency-department-100650603","NCT07750626","Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department","The Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Volunteering of the child and parent to participate in the study,\n* Children the ages between 5-10,\n* Having intramuscular (IM) injection.\n\nExclusion Criteria:\n\n* Communication problem,\n* Children with any chronic illness,\n* Taking any medication that has an analgesic effect at least 6 hours before applying.",{"count":89,"type":23},[26],"This prospective study is planned as a randomized controlled study. The aim of this study is to investigate the effects of vibration and the ShotBlocker method on pain and fear levels in children during intramuscular injection in the emergency department.",[485,29,486,487,488,489],"Children","Vibration","Shotblocker","Intramuscular Injection","Intramuscular Injection Pain",[485,62,486,491,488,146,492],"ShotBlocker","Emergency Department","2026-08-02",{"date":279,"type":41},{"date":493,"type":41},{"date":497,"type":23},"2026-11-16",{"name":499,"class":47},"Burdur Mehmet Akif Ersoy University",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":294,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":48},"100650020","effectiveness-of-a-mindfulness-based-intervention-for-pain-management-in-patients-with-multiple-sclerosis-mpims-100650020","NCT07741864","Effectiveness of a Mindfulness-Based Intervention for Pain Management in Patients With Multiple Sclerosis (MPIMS).","Effectiveness of a Mindfulness-Based Intervention for Pain Management in Patients With Multiple Sclerosis","MPIMS","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosis of multiple sclerosis with an Expanded Disability Status Scale (EDSS) score between 1.0 and 7.0.\n* Presence of pain.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Severe cognitive impairment.\n* Diagnosed psychiatric disorders (e.g., schizophrenia or personality disorders).\n* Participation in another non-pharmacological intervention specifically aimed at pain management.\n* If receiving stable pain medication, treatment must have been maintained for at least 4 months before enrollment.\n* Unwillingness to provide informed consent.",{"count":509,"type":23},84,[26],"The goal of this clinical trial is to evaluate whether a mindfulness-based intervention is effective for reducing pain in adults with multiple sclerosis. It will also assess whether this intervention improves other symptoms commonly associated with pain, such as fatigue, sleep disturbances, anxiety, depression, and quality of life.\n\nThe main questions it aims to answer are:\n\n* Does a mindfulness-based intervention reduce pain intensity in people with multiple sclerosis?\n* Does the intervention improve fatigue, sleep quality, emotional well-being, quality of life?\n* Does the effectiveness of the intervention differ according to the type of pain experienced by participants? Researchers will compare a mindfulness-based intervention with an educational program to determine whether mindfulness provides additional benefits for pain management in people with multiple sclerosis.\n\nParticipants will:\n\n* Be randomly assigned to either the mindfulness intervention group or the educational control group.\n* Complete assessments before the intervention, immediately after the intervention, and at 1-month and 3-month follow-up visits.\n* If assigned to the mindfulness group, attend eight weekly 2.5-hour group sessions plus one 6-hour retreat, either in person or online.\n* If assigned to the control group, attend two 2-hour educational sessions during the study period.\n* Complete questionnaires evaluating pain, fatigue, physical function, anxiety, depression, sleep quality, quality of life, and mindfulness throughout the study.",[513,62,29],"Multiple Sclerosis",[513,62,515],"Mindfulness","2026-07-30",{"date":444,"type":41},{"date":519,"type":23},"2026-09-02",{"date":521,"type":23},"2027-04-30",{"name":523,"class":47},"Hospital Universitario Virgen Macarena",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":48},"100648009","analgesic-efficacy-of-ultrasound-guided-deep-iliacus-plane-block-in-patients-undergoing-hip-fracture-surgery-100648009","NCT07716540","Analgesic Efficacy of Ultrasound-Guided Deep Iliacus Plane Block in Patients Undergoing Hip Fracture Surgery","Analgesic Efficacy of Ultrasound-Guided Deep Iliacus Plane Block in Patients Undergoing Hip Fracture Surgery: A Prospective, Randomized, Double-Blind, Sham-Controlled Clinical Trial","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled to undergo unilateral hip fracture surgery under spinal anesthesia\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Ability to understand and use the Numerical Rating Scale and patient-controlled analgesia device\n* No contraindication to spinal anesthesia or the deep iliacus plane block\n* Written informed consent provided by the participant or legally authorized representative\n\nExclusion Criteria:\n\n* ASA physical status IV or higher\n* Emergency surgery\n* Coagulopathy, bleeding diathesis, or anticoagulant treatment that contraindicates spinal anesthesia or peripheral nerve block\n* Infection at the planned needle insertion site\n* Known allergy to local anesthetics or any study medication\n* Pre-existing peripheral neuropathy, neurological disorder, or motor deficit involving the operated lower extremity\n* Inability to understand or use the Numerical Rating Scale or patient-controlled analgesia device\n* Cognitive impairment or communication difficulty preventing reliable postoperative assessment\n* Refusal to participate",{"count":532,"type":23},52,[26],"Hip fracture surgery is commonly associated with moderate to severe postoperative pain, which may delay mobilization and increase the need for opioid analgesics. The deep iliacus plane block is a recently described ultrasound-guided regional anesthesia technique designed to provide analgesia by allowing local anesthetic spread toward the femoral nerve, lateral femoral cutaneous nerve, and articular branches supplying the hip.\n\nThis prospective, randomized, double-blind, sham-controlled clinical trial will evaluate the analgesic efficacy of the deep iliacus plane block in adult patients undergoing hip fracture surgery under spinal anesthesia. After surgery, participants will be randomly assigned to receive either an ultrasound-guided deep iliacus plane block with local anesthetic or a sham block with normal saline.\n\nAll participants will receive standardized multimodal postoperative analgesia, including patient-controlled analgesia. The primary objective is to determine whether the deep iliacus plane block reduces postoperative opioid consumption during the first 24 hours after surgery. Postoperative pain scores, rescue analgesic requirements, sensory distribution, motor block, nausea and vomiting, quality of recovery, patient satisfaction, and block-related complications will also be evaluated.",[29],"2026-07-29",{"date":516,"type":41},{"date":539,"type":23},"2026-07-20",{"date":541,"type":23},"2027-01-01",{"name":543,"class":47},"Kanuni Sultan Suleyman Training and Research Hospital",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":552,"enrollmentInfo":553,"targetDuration":4,"studyType":24,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":557,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":48},"100646093","quadro-iliac-plane-block-for-analgesia-after-lumbar-microdiscectomy-100646093","NCT07695987","Quadro-Iliac Plane Block for Analgesia After Lumbar Microdiscectomy","Effect of Ultrasound-Guided Quadro-Iliac Plane Block Compared With Local Infiltration Analgesia After Single-Level Lumbar Microdiscectomy: A Prospective, Double-Blind, Controlled, Multicenter Randomized Trial","QIPB RCT","Inclusion Criteria:\n\n* Adults aged 18 to 75 years\n* American Society of Anesthesiologists physical status I to III\n* Scheduled for elective single-level lumbar microdiscectomy, such as L4-L5 or L5-S1 disc herniation\n* Planned surgery under general anesthesia\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to local anesthetics\n* Coagulopathy or active anticoagulant use\n* Infection, scar tissue, or skin lesion at the injection site\n* Pregnancy or breastfeeding\n* Chronic pain syndrome or regular opioid use\n* American Society of Anesthesiologists physical status IV or higher\n* Planned surgery for two or more levels of disc herniation","75 Years",{"count":168,"type":23},[26],"This study will evaluate whether ultrasound-guided quadro-iliac plane block provides better postoperative pain control than local infiltration analgesia in patients undergoing single-level lumbar microdiscectomy.\n\nAdult patients scheduled for elective single-level lumbar microdiscectomy will be randomly assigned to receive either bilateral quadro-iliac plane block plus patient-controlled analgesia or local infiltration analgesia plus patient-controlled analgesia. The main outcome of the study will be total fentanyl consumption during the first 24 hours after surgery. Pain scores, need for rescue analgesia, opioid-related side effects, patient satisfaction, and recovery quality will also be evaluated.",[29],{"date":516,"type":41},{"date":559,"type":41},"2026-07-10",{"date":561,"type":23},"2026-12-02",{"name":543,"class":47},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":570,"maxAge":294,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":48},"100642398","breestim-in-managing-neuropathic-pain-after-spinal-cord-injury-sci-100642398","NCT07659743","BreEStim in Managing Neuropathic Pain After Spinal Cord Injury (SCI)","A Randomized, Double-blind, Sham-controlled, Parallel-group Trial Designed to Evaluate the Efficacy of BreEStim in Managing Neuropathic Pain After Spinal Cord Injury (SCI)","Inclusion Criteria:\n\n* has a history of SCI \\> 1 year\n* has a DN4 (Douleur Neuropathique en 4 Questions) score of 4 or greater\n* has neuropathic pain \\>3 months\n* is stable on oral pain medications at least one month\n* Able to tolerate BreEStim treatment for 1 minute\n\nExclusion Criteria:\n\n* is on a mechanical ventilator\n* is currently having active urinary tract infection (UTI)\n* does not have any residual sensation in the arms\n* has other pain (musculoskeletal, visceral etc.), but not neuropathic, e.g., shoulder pain from wheelchair use\n* has a pacemaker to avoid possible side effect of electrical stimulation\n* is not able to follow commands, or to give consent\n* has asthma or other pulmonary disease\n* has a history of cardiac pathology, implanted pacemakers, or current use of rhythm altering medication like beta-blockers\n* has baclofen pump or deep brain implants\n* has respiratory tract\u002Fsinus infection and rhinorrhea\n* has low motor neuron injury that no responses will be triggered by electrical stimulation\n* has severe mental disorders (e.g., depression, substance abuse) and is receiving active treatment and frequent monitoring\n* is not medically stable","22 Years",{"count":572,"type":23},66,[26],"The purpose of this study is to compare the effectiveness of innovative intervention of breathing controlled electrical stimulation (BreEStim) and sham BreEStim and Transcutaneous Electrical Nerve Stimulation (TENS) in management of neuropathic pain in patients after spinal cord injury (SCI).",[29],[577,578],"neuropathic pain","BreEStim",{"date":580,"type":41},"2026-07-31",{"date":582,"type":23},"2026-10-01",{"date":584,"type":23},"2029-09-30",{"name":586,"class":47},"The University of Texas Health Science Center, Houston",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":138,"sex":18,"minAge":19,"maxAge":294,"enrollmentInfo":594,"targetDuration":4,"studyType":24,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":48},"100610370","phase-3-suzetrigine-in-total-hip-arthroplasty-100610370","NCT07226700","Suzetrigine in Total Hip Arthroplasty","A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary THA (posterior approach) with participating surgeons\n* Age 18 to 80 years old\n* Planned discharge to home\n* Planned use of neuraxial anesthesia\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n\nExclusion Criteria:\n\n* ASA greater than 3\n* Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)\n* History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)\n* History of QT prolongation\n* Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device\n* Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse\n* Inability to comply with any component of the study protocol\n* Younger than 18 or greater than 80 years old at the time of enrollment\n* Patient already on Suzetrigine\n* Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease\u002FChild Pugh B or C, use of strong CYP3 inhibitors or inducers)\n* Contraindications to neuraxial anesthesia or any other part of the study protocol\n* Participation in another investigational drug or device study\n* Pregnancy",{"count":595,"type":23},210,[192],"Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).",[599,600,601,602,603,604,605,29,62,606,607,608,609,610,611,612,613],"Total Hip Arthroplasty (THA)","Total Hip Arthroplasty \\(THA\\)","Total Hip Replacement","Total Hip Replacement Surgery","Total Hip Replacements","Total Hip Replacement Arthroplasty","Suzetrigine","Nav 1.8","JOURNAVX","Opioid Cessation","Opioid Consumption, Postoperative","Multimodal Analgesia","Randomized Controlled Trial","Randomized Controlled Study","Randomized Controlled Trials",{"date":516,"type":41},{"date":616,"type":41},"2025-11-03",{"date":618,"type":23},"2028-11-01",{"name":620,"class":47},"Hospital for Special Surgery, New York",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":24,"phases":630,"briefSummary":631,"conditions":632,"keywords":633,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":646},"100650027","phase-3-methoxyflurane-versus-usual-care-for-non-traumatic-pain-in-emergency-departments-100650027","NCT07742007","Methoxyflurane Versus Usual Care for Non-Traumatic Pain in Emergency Departments","Methoxyflurane Versus Usual Care for Non-Traumatic Pain in Emergency Departments: the Multicenter, Open-label, Superiority PAIN-THROX Randomized Controlled Trial","PAIN-THROX","Inclusion Criteria:\n\n* Adult ≥ 18 years\n* Acute non-traumatic pain of moderate to severe intensity (VAS strictly greater than 39 mm)\n* Able to independently assess their pain using a VAS and to record it independently on paper.\n* Affiliated to a social security system\n* Having signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n\n  * Contraindications to methoxyflurane as stated in the Summary of Product Characteristics:\n  * Hypersensitivity to the active substance or to any other fluorinated anesthetic or to any excipient.\n\n    * Malignant hyperthermia: known malignant hyperthermia or genetic predisposition.\n    * History of serious adverse reactions (patient or relatives) after administration of inhaled anesthetics.\n    * History of signs of liver injury after use of methoxyflurane or halogenated hydrocarbons.\n    * Clinically significant renal impairment\n    * Altered level of consciousness regardless of cause, including head trauma, drug or alcohol use\n    * Clinical evidence of cardiovascular instability\n    * Clinical evidence of respiratory depression\n  * Hemodynamically unstable patient (SBP \\\u003C 100 mmHg, DBP \\\u003C 30 mmHg)\n  * Patient having already received Methoxyflurane on the same day\n  * Patient having taken analgesic treatment prior to emergency consultation within 4 hours of admission.\n  * Pain ≤ 39 mm\n  * Pregnant, breastfeeding.\n  * Women of childbearing potential not using a highly effective method of contraception throughout the study. The absence of pregnancy must be confirmed by performing a pregnancy test. Patients who are unable to provide a urine sample at the time of inclusion will not be enrolled in the study.\n  * Subject under legal protection\n  * Patients currently within the exclusion period of another clinical trial.",{"count":142,"type":23},[192],"Pain is one of the most frequent patient-reported symptoms in emergency departments (EDs). Pain management could be very challenging, notably for patients that must wait in an ED waiting room. In such context, antalgic drugs that could be used are mainly oral medications with the paracetamol (acetaminophen), the non-steroidal anti-inflammatory drugs and the weak and strong opioid drugs as the main available options, depending on the degree of pain. Those commonly used painkillers, with oral administration, need a delay (approximatively 20 to 30 minutes) before the full analgesic effect could be observed. Methoxyflurane is a self-administered inhaled analgesic used for over 40 years in countries such as Australia. Methoxyflurane has a rapid onset of action, is well tolerated and is widely used for moderate to severe traumatic pain, with several trials that have investigated it efficacy in such indication. However, no data are available concerning the management of non-traumatic painful diseases. Thus, the aim of the open-label, multicenter, and two parallel-arms superiority PAIN-THROX randomized controlled trial is to assess how using self-administered inhaled Methoxyflurane could reduce the time to pain relief comparatively with oral analgesic medications for patients seeking in an ED for non-traumatic painful diseases and who could wait in an ED waiting room.",[29],[634,635,636,637],"Non-traumatic pain","methoxyflurane","Emergency department","analgesic management","2026-07-28",{"date":444,"type":41},{"date":641,"type":23},"2026-09-16",{"date":643,"type":23},"2027-09-16",{"name":645,"class":47},"University Hospital, Tours",3,{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":552,"enrollmentInfo":654,"targetDuration":4,"studyType":24,"phases":656,"briefSummary":657,"conditions":658,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":660,"lastUpdatePostDateStruct":661,"startDateStruct":662,"completionDateStruct":664,"leadSponsor":666,"locationsCount":48},"100649541","venlafaxine-for-non-specific-low-back-pain-100649541","NCT07737158","Venlafaxine for Non-specific Low Back Pain","Efficacy and Safety of Venlafaxine in the Treatment of Non-specific Low Back Pain","Inclusion Criteria:\n\n* Adults aged 18 to 75 years.\n* Diagnosis of chronic nonspecific low back pain, defined as pain located below the costal margin and above the inferior gluteal folds, lasting for more than 3 months, without a specific pathological cause.\n* Moderate to severe pain, defined as a Numerical Rating Scale score of 3 or higher.\n* Able to understand the study procedures and sign written informed consent.\n\nExclusion Criteria:\n\n* Low back pain caused by a known specific pathological condition, including but not limited to fracture, malignancy, infection, inflammatory disease, or other identifiable structural or systemic causes.\n* Major comorbidities that may interfere with study outcomes or represent contraindications to the study medication.\n* Current or previous diagnosis of depression, regardless of whether treatment was received.\n* Current or previous use of antidepressant medication.\n* Current use of opioid analgesics.\n* Pregnancy, breastfeeding, or planned pregnancy during the study period.\n* Known allergy, hypersensitivity, or contraindication to toludesvenlafaxine.\n* History of psychosis or other major psychiatric disorders.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.",{"count":655,"type":23},228,[26],"Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug Venlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.",[659,29],"Non-specific Low Back Pain","2026-07-27",{"date":516,"type":41},{"date":663,"type":23},"2026-09-01",{"date":665,"type":23},"2028-12-30",{"name":667,"class":47},"Beijing Tiantan Hospital"]